The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

被引:15
|
作者
Rosende-Roca, Maitee [1 ,2 ]
Abdelnour, Carla [1 ,2 ,3 ]
Esteban, Ester [1 ,2 ]
Tartari, Juan Pablo [1 ,2 ]
Alarcon, Emilio [1 ,2 ]
Martinez-Atienza, Juliana [1 ,2 ]
Gonzalez-Perez, Antonio [1 ,2 ]
Saez, Maria E. [1 ,2 ]
Lafuente, Asuncion [1 ,2 ]
Buendia, Mar [1 ,2 ]
Pancho, Ana [1 ,2 ]
Aguilera, Nuria [1 ,2 ]
Ibarria, Marta [1 ,2 ]
Diego, Susana [1 ,2 ]
Jofresa, Sara [1 ,2 ]
Hernandez, Isabel [1 ,2 ,3 ]
Lopez, Rogelio [1 ,2 ]
Gurruchaga, Miren Jone [1 ,2 ]
Tarraga, Lluis [1 ,2 ,3 ]
Valero, Sergi [1 ,2 ,3 ]
Ruiz, Agustin [1 ,2 ,3 ]
Marquie, Marta [1 ,2 ,3 ]
Boada, Merce [1 ,2 ,3 ]
机构
[1] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Res Ctr, Gran Via Carles III,85 BIS, Barcelona 08028, Spain
[2] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Memory Clin, Gran Via Carles III,85 BIS, Barcelona 08028, Spain
[3] Inst Salud Carlos III, Networking Res Ctr Neurodegenerat Dis CIBERNED, Madrid, Spain
关键词
Alzheimer's disease; Dementia; Mild cognitive impairment; Sex; Gender; Women; Aging; Education; Elderly; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DISEASE; DEMENTIA; OLDER; RISK; RECOMMENDATIONS; EPIDEMIOLOGY;
D O I
10.1186/s13195-021-00833-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population distribution and a lack of information on the sex-disaggregated effects of anti-dementia therapies. This is the first study aiming to identify the role of sex in the selection for screening in AD clinical trials. Methods This cross-sectional study provides a comprehensive analysis of screening eligibility according to a set of pre-selection criteria currently applied at Fundacio ACE memory clinic for a more efficient trial screening process. A cohort of 6667 women and 2926 men diagnosed with AD dementia (55%) or mild cognitive impairment (45%) was analyzed. We also assessed the frequencies of men and women effectively screened for trial enrolment over a period of 10 years. Additionally, data from AddNeuroMed study was used to explore trends in eligibility based on the education criteria. Results Women showed a significantly lower chance of being eligible for screening than men (OR = 1.26; p < 0.01). This imbalance was confirmed by a lower frequency of women screened for enrolment compared to the study population (63.0% vs. 69.5%). Education was revealed as the key criterion contributing to this unbalance, with men showing over twice the chance of being screened compared with women (OR = 2.25, p < 0.01). Education-based differences were greater in earlier born patients, but the gap narrowed and achieved balance with increasing year of birth. This observation was replicated using data from other European populations included in AddNeuroMed study. Comorbidity was the most limiting criterion with sex differences in frequencies and significant discrimination against the selection of men (OR = 0.86, p < 0.01). Conclusions The large number of low-educated elderly women with AD demands for a sex-focused approach in clinical research. New assessment tools insensitive to education level should be developed to enable a proportional representation of women. Although this gender education gap is mostly inexistent in developed countries, economic or cultural factors may lead to different scenarios in other regions. Overlooking the impact of sex may lead to a handicap in AD research with a direct adverse impact on women's health.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer's patients: A double-blind placebo-controlled randomized clinical trial
    Rustamzadeh, Auob
    Sadigh, Nader
    Vahabi, Zahra
    Khamseh, Fatemeh
    Mohebi, Nafiseh
    Ghobadi, Zahra
    Moradi, Fatemeh
    IBRO NEUROSCIENCE REPORTS, 2024, 17 : 108 - 121
  • [32] Understanding treatment goals and their application in clinical trial design for patients with Alzheimer disease and caregivers
    Gomez-Ulloa, David
    Runken, M. Chris
    Rodriguez, Wilton, I
    Hernandez, Basilio
    Chivite, Montserrat
    Davis, E. Anne
    Nisbet, Paul
    DRUGS IN CONTEXT, 2024, 13
  • [33] Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer
    Li, Yan
    Fan, Lihong
    Zheng, Jianming
    Nie, Xiu
    Sun, Yu
    Feng, Qin
    Lian, Shenyi
    Bai, Wenqi
    Cai, Weijing
    Yang, Yanan
    Su, Bo
    Xi, Yanfeng
    Lin, Dongmei
    CANCER BIOLOGY & MEDICINE, 2022, 19 (08) : 1235 - 1248
  • [34] Sex Differences Among Opioid-Abusing Patients With Chronic Pain in a Clinical Trial
    Manubay, Jeanne
    Davidson, Jesse
    Vosburg, Suzanne
    Jones, Jermaine
    Comer, Sandra
    Sullivan, Maria
    JOURNAL OF ADDICTION MEDICINE, 2015, 9 (01) : 46 - 52
  • [35] Sex differences in imaging and clinical characteristics of patients from the WAKE--UP trial
    Wouters, Anke
    Scheldeman, Lauranne
    Liessens, Hannelore
    Dupont, Patrick
    Boutitie, Florent
    Cheng, Bastian
    Ebinger, Martin
    Endres, Matthias
    Fiebach, Jochen B.
    Gerloff, Christian
    Muir, Keith W.
    Nighoghossian, Norbert
    Pedraza, Salvador
    Simonsen, Claus Z.
    Thijs, Vincent
    Thomalla, Goetz
    Lemmens, Robin
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (03) : 641 - 647
  • [36] Effects of Bunium persicum and Piper nigrum in the Treatment of Patients With Alzheimer's Disease: A Double-Blinded Randomised Clinical Trial
    Rajaee, Arezoo
    Petramfar, Peyman
    Ansari, Ramin
    Asadi, Sara
    Vazin, Afsaneh
    Zarshenas, Mohammad Mehdi
    JOURNAL OF HERBAL MEDICINE, 2025, 49
  • [37] Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity A Randomized Clinical Trial
    Vossel, Keith
    Ranasinghe, Kamalini G.
    Beagle, Alexander J.
    La, Alice
    Pook, Kasey Ah
    Castro, Madelyn
    Mizuiri, Danielle
    Honma, Susanne M.
    Venkateswaran, Nisha
    Koestler, Mary
    Zhang, Wenbo
    Mucke, Lennart
    Howell, Michael J.
    Possin, Katherine L.
    Kramer, Joel H.
    Boxer, Adam L.
    Miller, Bruce L.
    Nagarajan, Srikantan S.
    Kirsch, Heidi E.
    JAMA NEUROLOGY, 2021, 78 (11) : 1345 - 1354
  • [38] The role of gender in a smoking cessation intervention: a cluster randomized clinical trial
    Puente, Diana
    Cabezas, Carmen
    Rodriguez-Blanco, Teresa
    Fernandez-Alonso, Carmen
    Cebrian, Transito
    Torrecilla, Miguel
    Clemente, Lourdes
    Martin, Carlos
    BMC PUBLIC HEALTH, 2011, 11
  • [39] The role of gender in a smoking cessation intervention: a cluster randomized clinical trial
    Diana Puente
    Carmen Cabezas
    Teresa Rodriguez-Blanco
    Carmen Fernández-Alonso
    Tránsito Cebrian
    Miguel Torrecilla
    Lourdes Clemente
    Carlos Martín
    BMC Public Health, 11
  • [40] Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease
    Svetnik, Vladimir
    Wang, Ting-Chuan
    Ceesay, Paulette
    Snyder, Ellen
    Ceren, Omar
    Bliwise, Donald
    Budd, Kerry
    Hutzelmann, Jill
    Stevens, Joanne
    Lines, Christopher
    Michelson, David
    Herring, W. Joseph
    JOURNAL OF SLEEP RESEARCH, 2021, 30 (06)